Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Phase I Open- Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Autologous Adipose Stem Cell (Adult Human) to Subjects With Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02161744
• Other study ID #: ICMS-2013-25
• Status: Terminated
• Phase: Phase 1
• Start date: October 10, 2013
• Est. completion date: October 29, 2018

Study information

• Verified date: January 2020
• Source: Arkansas Heart Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FEV1/FVC and 6 min walking distance) compared with a control baseline of 6 weeks.

Patients will be followed up for 12 months after the therapy.

Description:

STUDY DESIGN This is a Phase I open- label single-dose study in subjects with significant COPD. This is an expanded safety cohort. The investigators will enroll a minimum of 30 subjects. 6 week data of FEV1, FEV1/FVC, DLCO and 6 min walking distance values will be collected in all patients who are enrolled in the study (Baseline and 6 weeks after). Prior to the stem cell treatment, the patient will be assessed for 6 weeks by pulmonary function tests and 6 min walk tests. Then, patients will receive the infusion of stromal vascular fraction cells containing the aADSC (single intravenous dose). The standard therapy of COPD patients will not be interrupted during the duration of the study. Safety will be monitored on an ongoing basis, and an interim safety review will be conducted by the Investigator(s) and Sponsor after the first 20 patients have been enrolled and treated.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: October 29, 2018
• Est. primary completion date: October 29, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and Females =18 years.

2. Cognitive competitiveness.

3. Diagnosis of at least moderate COPD (postbronchodilator FEV1/FVC < 70% (<0.7), FEV1 < 80% predicted).

4. Diffusing capacity impairment (DLCO) assessed by single breath test (corrected for alveolar volume, 'DLVA').

5. Life expectancy greater than 12 months.

6. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.

7. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits.

8. No changes in active pulmonary medications for heart failure during the two weeks prior enrollment.

10. Written informed consent. 11. Non-smoker or Past smoker, with 20 pack-years or more history

Exclusion Criteria:

1. Current smokers.

2. Unstable coronary disease.

3. Patients with industrial exposure to silica and/or asbestos or giant bullae.

4. Uncontrolled seizure disorder.

5. Dementia.

6. Presence of immune deficiency or autoimmune disease.

7. Alpha- 1 antitrypsin deficiency.

8. Cor pulmonale or diastolic heart failure NYHA class III or IV

9. Type 1 diabetes mellitus

10. Complicated type 2 diabetes mellitus.

11. Active tuberculosis or severe lung damage due to tuberculosis (extensive cavitation).

12. History of cancer within the past 5 years.

13. Clinically-significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests.

14. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.

15. Porphyria.

16. Allergy to sodium citrate or any "caine" type of local anesthetic.

17. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Biological:
• ADSCs administration
100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.

Locations

Country	Name	City	State
United States	Arkansas Heart Hospital	Little Rock	Arkansas
United States	Arkansas Site Management Services LLC	Little Rock	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
Arkansas Heart Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of adipose derived stem cells (ADSC) in Patient with COPD	Safety/tolerability of Adipose Derived Stem Cell (ADSC) in patients with Chronic Obstructive Pulmonary Disease (COPD) during the twelve-month study period as determined by the incidence and severity of of adverse events.	12 months
Secondary	Efficacy of ADSC in improving Shortness of Breath (SOB)	The change (decrease) in patient Shortness Of Breath (SOB) as compared to baseline, measured in breath per minute, after administration of adipose derived stem cells (ADSC)	2, 6 and 12 months
Secondary	Efficacy of ADSC In Pulmonary Function Test (PFTs)	The change (improvement) in Pulmonary Function Test (PFTs) after administration of adipose derived stem cells (ADSC) as compared to baseline.	2, 6, 12 months
Secondary	Efficacy of adipose derived stem cell in 6 MWT	Improvement in patient ability to walk as measure using a 6 minute walk test ( in meter) as compared to baseline	2, 6, 12 months
Secondary	Efficacy of adipose derived stem cells in patient's perceived exertion.	The change from baseline in patient perceived exertion as measure using the modified BORG scale or Rate of perceive exertion (RPE) which ranges from 1(no perceived exertion at all) to 10 (maximum perceived exertion)	2, 6, 12 months
Secondary	Efficacy in Quality of life using George's Respiratory Questionnaire	The change from baseline in patient quality of life as measure using the George's Respiratory Questionnaire	2, 6, 12 months
Secondary	Efficacy in Quality of life using the Chronic Respiratory questionnaires	The change from baseline in patient quality of life as measure using the Chronic Respiratory Questionnaire	2, 6, 12 months